Araceli Biosciences, a Portland, OR-based biotechnology company for high-content imaging and AI-powered analysis, raised $11.2M in Seed funding.
Bill Cortelyou, Board Chairman, was the lead investor.
The company intends to use the funds to:
- scale operational infrastructure to meet growing demand.
- advance market applications, including personalized medicine.
- advance the platform’s hardware and software for real-time analysis capabilities.
- expand marketing and business development efforts.
Led by CEO Matt Beaudet, Araceli Biosciences is a biotechnology company focused on accelerating drug discovery through innovations in high-content imaging and AI-driven analysis. With its flagship Endeavor system and Clairvoyance software, it empowers scientists to generate actionable insights efficiently across a wide range of biological applications.
FinSMEs
24/04/2025